PMID- 35715866
OWN - NLM
STAT- MEDLINE
DCOM- 20220621
LR  - 20220716
IS  - 1470-7330 (Electronic)
IS  - 1740-5025 (Print)
IS  - 1470-7330 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Jun 17
TI  - Reliability of dynamic susceptibility contrast perfusion metrics in pre- and 
      post-treatment glioma.
PG  - 28
LID - 10.1186/s40644-022-00466-2 [doi]
LID - 28
AB  - BACKGROUND: In neuro-oncology, dynamic susceptibility contrast magnetic resonance 
      (DSC-MR) perfusion imaging emerged as a tool to aid in the diagnostic work-up and 
      to surveil effectiveness of treatment. However, it is believed that a significant 
      variability exists with regard to the measured in DSC-MR perfusion parameters. 
      The aim of this study was to assess the observer variability in measured DSC-MR 
      perfusion parameters in patients before and after treatment. In addition, we 
      investigated whether region-of-interest (ROI) shape impacted the observer 
      variability. MATERIALS AND METHODS: Twenty non-treated patients and a matched 
      group of twenty patients post-treatment (neurosurgical resection and 
      post-chemoradiotherapy) were included. Six ROIs were independently placed by 
      three readers: circular ROIs and polygonal ROIs covering 1) the tumor hotspot; 2) 
      the peritumoral region (T2/FLAIR-hyperintense region) and 3) the whole tumor 
      region. A two-way random Intra-class coefficient (ICC) model was used to assess 
      variability in measured DSC-MRI perfusion parameters. The perfusion metrics as 
      assessed by the circular and the polygonal ROI were compared by use of the 
      dependent T-test. RESULTS: In the non-treated group, circular ROIs showed 
      good-excellent overlap (ICC-values ranging from 0.741-0.963) with the exception 
      of those representing the tumor hotspot. Polygonal ROIs showed lower ICC-values, 
      ranging from 0.113 till 0.856. ROI-placement in the posttreatment group showed to 
      be highly variable with a significant deterioration of ICC-values. Furthermore, 
      perfusion metric assessment in similar tumor regions was not impacted by ROI 
      shape. DISCUSSION: This study shows that posttreatment quantitative 
      interpretation of DSC-MR perfusion imaging is highly variable and should be 
      carried out with precaution. Pretreatment assessment of DSC-MR images, however, 
      could be carried out be a single reader in order to provide valid data for 
      further analyses.
CI  - (c) 2022. The Author(s).
FAU - Kouwenberg, Valentina
AU  - Kouwenberg V
AD  - Department of Medical Imaging, Radboud University Medical Center, Geert 
      Grooteplein Zuid 10, 6525 EZ, Nijmegen, The Netherlands.
FAU - van Santwijk, Lusien
AU  - van Santwijk L
AD  - Department of Medical Imaging, Radboud University Medical Center, Geert 
      Grooteplein Zuid 10, 6525 EZ, Nijmegen, The Netherlands.
FAU - Meijer, Frederick J A
AU  - Meijer FJA
AD  - Department of Medical Imaging, Radboud University Medical Center, Geert 
      Grooteplein Zuid 10, 6525 EZ, Nijmegen, The Netherlands.
FAU - Henssen, Dylan
AU  - Henssen D
AUID- ORCID: 0000-0002-3915-3034
AD  - Department of Medical Imaging, Radboud University Medical Center, Geert 
      Grooteplein Zuid 10, 6525 EZ, Nijmegen, The Netherlands. 
      dylan.henssen@radboudumc.nl.
LA  - eng
PT  - Journal Article
DEP - 20220617
PL  - England
TA  - Cancer Imaging
JT  - Cancer imaging : the official publication of the International Cancer Imaging 
      Society
JID - 101172931
RN  - 0 (Contrast Media)
SB  - IM
MH  - Benchmarking
MH  - *Brain Neoplasms/diagnostic imaging/pathology/therapy
MH  - Contrast Media
MH  - *Glioma/diagnostic imaging/pathology/therapy
MH  - Humans
MH  - Magnetic Resonance Imaging/methods
MH  - Perfusion
MH  - Reproducibility of Results
PMC - PMC9205029
OTO - NOTNLM
OT  - Dynamic susceptibility contrast magnetic resonance (DSC-MR) perfusion imaging
OT  - Glioma
OT  - Interobserver variability
OT  - Region of interest
COIS- No competing interests.
EDAT- 2022/06/18 06:00
MHDA- 2022/06/22 06:00
PMCR- 2022/06/17
CRDT- 2022/06/17 23:46
PHST- 2022/02/01 00:00 [received]
PHST- 2022/05/26 00:00 [accepted]
PHST- 2022/06/17 23:46 [entrez]
PHST- 2022/06/18 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
PHST- 2022/06/17 00:00 [pmc-release]
AID - 10.1186/s40644-022-00466-2 [pii]
AID - 466 [pii]
AID - 10.1186/s40644-022-00466-2 [doi]
PST - epublish
SO  - Cancer Imaging. 2022 Jun 17;22(1):28. doi: 10.1186/s40644-022-00466-2.